Market closedNon-fractional
Atara Biotherapeutics/ATRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Ticker
ATRA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Thousand Oaks, United States
Employees
173
Website
www.atarabio.com
ATRA Metrics
BasicAdvanced
$37M
Market cap
-
P/E ratio
-$50.75
EPS
0.53
Beta
-
Dividend rate
Price and volume
Market cap
$37M
Beta
0.53
Financial strength
Current ratio
0.589
Quick ratio
0.455
Long term debt to equity
-42.923
Total debt to equity
-57.197
Interest coverage (TTM)
-43.28%
Management effectiveness
Return on assets (TTM)
-59.04%
Return on equity (TTM)
1,398.03%
Valuation
Price to revenue (TTM)
1.023
Price to book
-0.36
Price to tangible book (TTM)
-0.36
Price to free cash flow (TTM)
-0.192
Growth
Revenue change (TTM)
-39.63%
Earnings per share change (TTM)
-3.13%
3-year revenue growth
113.78%
3-year earnings per share growth
-18.99%
ATRA News
AllArticlesVideos
![Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://cdn.snapi.dev/images/v1/v/t/press6-2511293.jpg)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·23 hours ago
![Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum](https://cdn.snapi.dev/images/v1/d/m/press9-2509476.jpg)
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Business Wire·3 days ago
![Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy](https://cdn.snapi.dev/images/v1/i/o/biotech18-2509103.jpg)
Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Seeking Alpha·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atara Biotherapeutics stock?
Atara Biotherapeutics (ATRA) has a market cap of $37M as of July 06, 2024.
What is the P/E ratio for Atara Biotherapeutics stock?
The price to earnings (P/E) ratio for Atara Biotherapeutics (ATRA) stock is 0 as of July 06, 2024.
Does Atara Biotherapeutics stock pay dividends?
No, Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Atara Biotherapeutics dividend payment date?
Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Atara Biotherapeutics?
Atara Biotherapeutics (ATRA) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell Atara Biotherapeutics stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Atara Biotherapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.